The challenge of acute coronary syndromes in South Africa by Manga, Pravin
Atherosclerotic coronary artery disease remains highly prevalent in South Africa. Whereas in the past the disease 
predominantly affected the white and Indian population groups, there is a slow but steady rise in the prevalence 
of coronary artery disease in the black African population. This is in concert with fi ndings from other developing 
nations where the prevalence of atherosclerotic coronary artery disease is also increasing. The reasons for this 
increase in prevalence are multifactorial including rapid urbanization, high smoking rates, lack of exercise and 
adoption of western dietary patterns. The net result is that the burden of atherosclerotic heart disease is increasing 
in South Africa. There are few prevalence studies but it is estimated that 80 000 patients present with acute 
coronary syndromes per year in South Africa.
Over the last two decades considerable advances have been made with regard to our understanding of the 
mechanisms underlying acute coronary syndromes. In response to these advances a number of treatment 
strategies have been developed and tested in many randomized trials. Despite our current understanding of the 
disease process and modern treatment strategies, the risk of death or non-fatal myocardial infarction (MI) is about 
10% at 30 days and the risk of an adverse outcome at 6 months remains high at 30%.  Therefore, the management 
of acute coronary syndromes remains an ongoing challenge. Appropriately, this issue of SA Heart focuses on 
aspects of management of patients with acute coronary syndromes. 
The treatment of acute myocardial infarction can be problematical, especially in environments with constrained 
resources and other logistical barriers.  As a result primary PCI is applicable to only a small number of patients in 
South Africa and the majority of patients receive thrombolytic therapy.  Thus refi nement of management of the 
post-thrombolytic period becomes more relevant. In his article Hellig elegantly discusses the strategies of 
mechanical intervention in acute myocardial infarction and highlights the role of fascilitated and rescue PCI. In 
addition, his paper addresses mechanical methods such as distal protection and thrombectomy devices that may 
fascilitate procedural success during PCI.
One of the most hotly debated issues in the management of non-ST elevation MI revolves around the timing of 
cardiac catheterization. This debate is also more important in countries like South Africa where practice patterns 
(largely dictated by health resources) differ.  Vorster et al. critically evaluate the role of early versus late intervention 
in patients with non-ST elevation myocardial infarction and highlight the role of risk stratifi cation in the 
selection process.
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Management of lipids has become the cornerstone of primary and secondary prevention of atherosclerotic 
coronary artery disease. However, lipid lowering in acute coronary syndromes has received less attention. 
Mamdoo et al. in their paper discuss the role of lipid lowering in acute coronary syndromes and debate the issue 
as to how low LDL cholesterol should be reduced by pharmacological means.
Cardiac biomarkers have traditionally played a signifi cant role in the diagnosis of acute coronary syndromes. They 
are now recognized to be of importance in risk stratifi cation as well. Besides the traditional biomarkers, newer 
biomarkers have come to the fore. Ranjith et al. review the current role of the established biomarkers and 
appraise the potential role of the newer biomarkers in the diagnosis, risk stratifi cation and management of 
patients with acute coronary syndromes.
One of the fundamental management strategies of acute coronary syndromes involves the use of potent anti- 
platelet and antithrombotic therapies. These aggressive therapies lead to increased bleeding risk. Thus the most 
recent ESC guidelines take into account the benefi t-risk ratio, expressed as number needed to treat and number 
needed to harm to produce one event.(1)  Khan in her paper importantly details the risks of bleeding and anemia 
in acute coronary syndromes and discusses its impact on outcome. 
We have come a long way in treating patients with acute coronary syndromes. There is little doubt that ongoing 
efforts with new therapies and refi nement of current treatment strategies will benefi t our patients in the short 
and long term. 
References:
1.  Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute 
coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary 
Syndromes of the European Society of Cardiology. Eur Heart J. 2007;28:1598-1660
